• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Nemolizumab for pruritis in atopic dermatitis patients

byConstance Wu
August 14, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this study, nemolizumab with topical agents and oral antihistamines when compared to topical agents and oral antihistamines alone reduced pruritis in atopic dermatitis patients

2. Among patients in the nemolizumab group, eczema area, quality of life and insomnia improved when compared with placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The use of an interleukin-31 receptor antibody, nemolizumab, has been shown in previous studies to reduce inflammation and epidermal-barrier disruption in atopic dermatitis, which can reduce pruritis. The purpose of this trial was to evaluate the efficacy and safety of the addition of nemolizumab to concomitant topical agents and oral antihistamines for patients with moderate-to-severe pruritis, refractory to topical agents. The results of the study demonstrated that the addition of nemolizumab significantly reduced the pruritis visual-analogue scale (VAS) score after 16 weeks of treatment. Other measurements of quality of life were also significantly improved with nemolizumab such as improvement in the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), and the Insomnia Severity Index (ISI). The main safety profile difference was an increased incidence of injection-related reactions compared to placebo. However, several limitations caution the generalizability of the study. This included the inclusion of only Japanese patients, the short duration of follow-up and the inclusion of only patients above the age of 13 years which excluded an important cohort with atopic dermatitis.

Click to read the study, published today in NEJM

Relevant Reading: IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity

In-Depth [randomized controlled trial]: This 16-week, double-blind, phase 3 trial included 143 Japanese patients with atopic dermatitis, moderate-to-severe pruritis and an inadequate response to topical agents and oral antihistamines. To be included in the study, patients had to be at least 13 years of age and have an inadequate pruritic response to topical glucocorticoids, topical calcineurin inhibitors and oral antihistamines. Patients were randomly assigned in a 2:1 ratio to receive nemolizumab or placebo, with both groups receiving topical agents and oral antihistamines. The primary efficacy endpoint demonstrated that the percent change in pruritis VAS score was -42.8% in the treatment group compared to -21.4% in placebo (95% CI -30.2 to -12.7). Secondary endpoints showed nemolizumab improved the EASI score (-45.9 vs. -33.2 [95% CI -26.6 to -11.9]), increased the percentage of patients with a DLQI score of ≤4 (17% difference [95% CI 2 to 31]), and increased the percentage of patients with an ISI score of ≤7 (33% difference [95% CI 17 to 48]). The most commonly reported adverse event was worsening atopic dermatitis which was present in 24% of the treatment group and 21% in placebo. Cytokine abnormalities such as an increased thymus and activation-regulated chemokine level was observed only in the treatment group but was not associated with worsening atopic dermatitis. Notably, 8% of the nemolizumab group had injection-related reactions compared to 3% in placebo.

RELATED REPORTS

Dupilumab plus topical corticosteroids are effective in the treatment of childhood atopic dermatitis

Abrocitinib is more effective than dupilumab for treatment of moderate-to-severe atopic dermatitis

Early exposure to allergenic foods may reduce incidence of long-term food allergy

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atopic dermatitisdermatitisnemolizumabpruritis
Previous Post

Afabicin noninferior to vancomycin and linzeolid for treatment of staphylococcal infections

Next Post

Nearly half of all HFrEF patients are not receiving therapy according to National guidelines, leading to poor outcomes

RelatedReports

Pimecrolimus effective first-line treatment for atopic dermatitis
Chronic Disease

Dupilumab plus topical corticosteroids are effective in the treatment of childhood atopic dermatitis

September 27, 2022
Topical pimecrolimus use for atopic dermatitis not linked to malignancy
Chronic Disease

Abrocitinib is more effective than dupilumab for treatment of moderate-to-severe atopic dermatitis

August 2, 2022
Peripregnancy nut consumption may decrease development of nut allergies
Chronic Disease

Early exposure to allergenic foods may reduce incidence of long-term food allergy

July 5, 2022
#VisualAbstract Dupilumab may contribute to ocular surface disease in patients with atopic dermatitis
StudyGraphics

#VisualAbstract Dupilumab may contribute to ocular surface disease in patients with atopic dermatitis

September 10, 2021
Next Post
Long-term outcomes for off-pump and on-pump CABG are similar

Nearly half of all HFrEF patients are not receiving therapy according to National guidelines, leading to poor outcomes

Preoperative tumor embolization does not reduce operative blood loss

Robotic approach to paraesophageal hernia repair associated with positive patient outcomes

#VisualAbstract: Serum antibody testing for SARS-CoV-2

#VisualAbstract: Serum antibody testing for SARS-CoV-2

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options